SG11201912281PA - 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof - Google Patents

2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof

Info

Publication number
SG11201912281PA
SG11201912281PA SG11201912281PA SG11201912281PA SG11201912281PA SG 11201912281P A SG11201912281P A SG 11201912281PA SG 11201912281P A SG11201912281P A SG 11201912281PA SG 11201912281P A SG11201912281P A SG 11201912281PA SG 11201912281P A SG11201912281P A SG 11201912281PA
Authority
SG
Singapore
Prior art keywords
methylaminomethyl
benzofuran
fluoro
phenyl
preparation
Prior art date
Application number
SG11201912281PA
Other languages
English (en)
Inventor
Chunhao Yang
Zehong Miao
Cun Tan
Xiajuan Huan
Jian Ding
Yi Chen
Original Assignee
Shanghai Institute Of Materia Medica Chinese Academy Of Sciences
Fukang Shanghai Health Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute Of Materia Medica Chinese Academy Of Sciences, Fukang Shanghai Health Technology Co Ltd filed Critical Shanghai Institute Of Materia Medica Chinese Academy Of Sciences
Publication of SG11201912281PA publication Critical patent/SG11201912281PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201912281PA 2017-06-14 2018-05-31 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof SG11201912281PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710449281.2A CN109134409B (zh) 2017-06-14 2017-06-14 盐酸美呋哌瑞多晶型物及其制备方法与应用
PCT/CN2018/089222 WO2018228205A1 (zh) 2017-06-14 2018-05-31 盐酸美呋哌瑞多晶型物及其制备方法与应用

Publications (1)

Publication Number Publication Date
SG11201912281PA true SG11201912281PA (en) 2020-01-30

Family

ID=64660851

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912281PA SG11201912281PA (en) 2017-06-14 2018-05-31 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof

Country Status (11)

Country Link
US (1) US11174237B2 (enExample)
EP (1) EP3643708B1 (enExample)
JP (2) JP7432503B2 (enExample)
KR (1) KR102458566B1 (enExample)
CN (1) CN109134409B (enExample)
AU (1) AU2018286057B2 (enExample)
CA (1) CA3067336C (enExample)
SG (1) SG11201912281PA (enExample)
TW (1) TWI675027B (enExample)
WO (1) WO2018228205A1 (enExample)
ZA (1) ZA202000224B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109134409B (zh) * 2017-06-14 2023-09-29 中国科学院上海药物研究所 盐酸美呋哌瑞多晶型物及其制备方法与应用
CN111320596B (zh) * 2018-12-14 2024-07-05 甫康（上海）健康科技有限责任公司 盐酸美呋哌瑞多晶型物及其制备方法
EP4112049A4 (en) * 2020-02-24 2024-07-24 Fukang (Shanghai) Health Technology Co., Ltd. ANTI-CORONAVIRUS APPLICATION OF POLY ADP-RIBOSE POLYMERASE INHIBITOR

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103242273B (zh) * 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用
CN104003979B (zh) * 2013-02-21 2016-08-17 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪类化合物、其药物组合物及其制备方法和用途
CN105246875A (zh) * 2013-09-03 2016-01-13 四川海思科制药有限公司 茚满衍生物及其制备方法和在医药上的应用
CN104003940B (zh) * 2014-06-16 2017-02-15 华东理工大学 2,4‑二氟‑5‑(酞嗪酮‑1‑甲基)‑苯甲酰哌嗪类化合物及其用途
CN109134409B (zh) * 2017-06-14 2023-09-29 中国科学院上海药物研究所 盐酸美呋哌瑞多晶型物及其制备方法与应用
CN111320596B (zh) * 2018-12-14 2024-07-05 甫康（上海）健康科技有限责任公司 盐酸美呋哌瑞多晶型物及其制备方法

Also Published As

Publication number Publication date
US20200172502A1 (en) 2020-06-04
TW201904952A (zh) 2019-02-01
US11174237B2 (en) 2021-11-16
AU2018286057A1 (en) 2020-01-30
TWI675027B (zh) 2019-10-21
EP3643708C0 (en) 2025-09-24
ZA202000224B (en) 2021-08-25
EP3643708A4 (en) 2021-02-24
KR102458566B1 (ko) 2022-10-24
JP2022060192A (ja) 2022-04-14
CN109134409B (zh) 2023-09-29
EP3643708A1 (en) 2020-04-29
CA3067336A1 (en) 2018-12-20
EP3643708B1 (en) 2025-09-24
JP2020524707A (ja) 2020-08-20
CA3067336C (en) 2022-11-15
JP7432503B2 (ja) 2024-02-16
AU2018286057B2 (en) 2021-03-18
WO2018228205A1 (zh) 2018-12-20
KR20200014924A (ko) 2020-02-11
CN109134409A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
IL288104A (en) Heterocyclic compounds, preparation methods and their use
SG11202106706TA (en) Heterocyclic compound intermediate, preparation method therefor and application thereof
IL271726A (en) Compositions and methods of use of 2-(4-chlorophenyl)-N-((2-(2, 6-doxopyridin-3-yl)-1-oxoisoinodolin-5-yl)methyl)2-2-difluoroacetamide
LT3034497T (lt) 3,5-diamino-6-chlor-n-(n-(4-(4-(2-(heksil(2,3,4,5,6-penta-hidroksiheksil)amino)etoksi)fenil)butil)karbamimidoil)pirazin-2-karboksamidas
DK2800746T3 (da) Fremgangsmåde til fremstilling af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazin
PT3470400T (pt) Formas cristalinas de ozanimod e cloridrato de ozanimod, e processos para a preparação das mesmas
IL230152A (en) METHOD FOR PREPARING n- [5- (aminosulfonyl) -4-methyl-3,1-thiazole-2-ram] n -methyl- 2 - [4 - (2-pyridinyl) phenyl] Acetamide and its monohydrate-saturated salt
ZA201804482B (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
DK3558945T3 (da) Fremgangsmåde til fremstilling af et n-[2-(2-pyridinyl)ethyl]carboxamidderivat
DK3227294T3 (da) 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-oner som inhibitorer af myeloperoxidase
SG11202007554TA (en) Dioxazoline compound, preparation method therefor, and uses thereof
ZA202000224B (en) 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof
IL272559B (en) A method for the preparation of 4-(heptafluoro-2-propyl) aniline
ZA202401526B (en) 2-homopiperazine-1-yl-4h-1,3-benzothiazine-4-one derivatives and process for the preparation of 2- (homo)piperazine 1,3-benzothiazine-4-one hydrochlorides
IL282817A (en) New material, production method, and its use
SI3292133T1 (sl) Postopek priprave 2-(4-(2-(((2-(4-klorofenil)-1,3-tiazol-4-il)metil)sulfanil)-3,5-dician- 6-(pirolidin-1-il)piridin-4-il)fenoksi)etil-L-alanil-L-alaninat hidroklorida
EP3216791A4 (en) Polymorphic substance of yonkenafil hydrochloride, preparation method therefor, and composition and use thereof
IL265893A (en) Crystal forms of 4-(2-((r1(2r,-2-hydroxycyclohexylamino)benzothiazol-6-yloxy)-n-methylpicolinamide
PL3750893T3 (pl) Związek dioksazoliny, sposób jego wytwarzania oraz jego zastosowania
EP3461823A4 (en) PLX3397 HYDROCHLORIDE CRYSTAL FORM, MANUFACTURING METHOD AND USE THEREOF
SG11201701674RA (en) Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
EP3750894A4 (en) UREA-SUBSTITUTED AROMATIC CYCLE BOUND DIOXAZOLINE COMPOUND, PROCESS OF PREPARATION AND APPLICATIONS
SI3643704T1 (sl) Novi intermediati za pripravo remifentanil hidroklorida
DK3164385T3 (da) Ny polymorf form af n-[2-(6-fluor-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluorpropoxy)benzylaminhydrochlorid for behandlingen af alzheimers
HK1240926A1 (en) Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same